- Palisade Bio ( NASDAQ: PALI ) has announced early exercise of 445,000 common stock purchase warrants issued pursuant to the company's August 2022 public offering.
- As a result of the exercises, the biopharmaceutical company received gross cash proceeds of ~$1.25M.
- "The voluntary early exercise of these Warrants further extends our cash runway into early 2024, which is beyond our expected topline results in the second half of next year," commented JD Finley, interim CEO of Palisade Bio.
- PALI shares are down 6% premarket
For further details see:
Palisade Bio raises $1.25M from early exercise of warrants